Cooley advised a syndicate of globally recognized private and public investors in connection with the management-led majority stake acquisition of HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, valuing the company at approximately $2.25 billion. The investors include K5 Global, Bezos Expeditions and Wellington Management; top-tier global investment firms such as Alpha JWC Ventures; and existing investors Alpha Wave Ventures, Venture Investors Health Fund, Lumira Ventures, Hatteras Venture Partners, Early Stage Partners, Amzak Health, HealthQuest Capital, Yonjin Venture, the State of Wisconsin Investment Board, the State of Michigan Retirement System and Johnson & Johnson Innovation JJDC, among others.
Cooley Advises Investor Syndicate on $2.25 Billion Acquisition of HistoSonics